Kivexa
abacavir / lamivudine
Table of contents
Overview
Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Kivexa contains two active substances, abacavir and lamivudine.
Authorisation details
Product details | |
---|---|
Name |
Kivexa
|
Agency product number |
EMEA/H/C/000581
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
HIV Infections
|
Anatomical therapeutic chemical (ATC) code |
J05AR02
|
Publication details | |
---|---|
Marketing-authorisation holder |
ViiV Healthcare BV
|
Revision |
36
|
Date of issue of marketing authorisation valid throughout the European Union |
16/12/2004
|
Contact address |
Van Asch van Wijckstraat 55H |
Product information
19/08/2022 Kivexa - EMEA/H/C/000581 - IG1531
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Antivirals for treatment of HIV infections, combinations
-
Antivirals for systemic use
Therapeutic indication
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.
Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.